82 trials changed in the last 30 days: 0 stopped, 29 with notable changes, 53 with minor changes only.
Primary and study completion pushed from Oct 15, 2026 to Apr 15, 2027
Also in this update: Enrollment increased: 137 → 193 participants
AstraZenecaNot specified NCT05645172 Registry history of NCT05645172 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 4, 2027 to Apr 6, 2028
AstraZenecaPhase 3 NCT07775404 Registry history of NCT07775404 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 14, 2027 to Jan 10, 2028
Also in this update: Study completion pushed from Aug 4, 2028 to Apr 9, 2029
AstraZenecaPhase 3 NCT06455449 Registry history of NCT06455449 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 16, 2027 to Mar 16, 2029
Also in this update: Enrollment increased: 280 → 392 participants; Interventions modified
AstraZenecaPhase 1/2 NCT06005493 Registry history of NCT06005493 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 16, 2030 to Sep 30, 2032
AstraZenecaPhase 4 NCT06651970 Registry history of NCT06651970 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Feb 28, 2029 to Dec 30, 2029
AstraZenecaNot specified NCT06544629 Registry history of NCT06544629 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 30, 2027 to Jun 30, 2030
Also in this update: Primary endpoint(s) modified
AstraZenecaNot specified NCT07390240 Registry history of NCT07390240 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Apr 30, 2027
AstraZenecaNot specified NCT07315958 Registry history of NCT07315958 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 89 → 76 locations
AstraZenecaPhase 3 NCT07007793 Registry history of NCT07007793 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 3 → Phase 2; Primary and study completion moved earlier from Oct 31, 2028 to Aug 30, 2028
AstraZenecaPhase 2 NCT06960577 Registry history of NCT06960577 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Recruitment opened; Trial sites expanded: 45 → 478 locations
AstraZenecaPhase 3 NCT07624305 Registry history of NCT07624305 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 25, 2026; Trial completed
AstraZenecaPhase 2 NCT05498155 Registry history of NCT05498155 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Enrollment closed, study ongoing; Trial sites expanded: 18 → 21 locations
AstraZenecaNot specified NCT07446738 Registry history of NCT07446738 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 79 → 124 locations; Start date changed from estimate of Sep 29, 2026 to Sep 24, 2026
AstraZenecaPhase 3 NCT07816666 Registry history of NCT07816666 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 51 locations
AstraZenecaPhase 3 NCT07686120 Registry history of NCT07686120 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 2 → 210 locations
AstraZenecaPhase 3 NCT07711002 Registry history of NCT07711002 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 45 locations
AstraZenecaPhase 3 NCT07619118 Registry history of NCT07619118 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 41 → 128 locations
AstraZenecaPhase 3 NCT07691970 Registry history of NCT07691970 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 44 → 71 locations
AstraZenecaPhase 3 NCT07751848 Registry history of NCT07751848 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 218 → 227 locations
AstraZenecaPhase 3 NCT07784270 Registry history of NCT07784270 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Trial sites reduced: 160 → 86 locations; Primary completion date changed from estimate of Nov 3, 2028 to Sep 21, 2026
AstraZenecaPhase 3 NCT06750289 Registry history of NCT06750289 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Sep 30, 2026 to Jan 11, 2027; Trial sites reduced: 303 → 211 locations
AstraZenecaPhase 3 NCT06417814 Registry history of NCT06417814 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaPhase 3 NCT05267613 Registry history of NCT05267613 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaPhase 2 NCT07218900 Registry history of NCT07218900 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaPhase 1 NCT03423628 Registry history of NCT03423628 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of May 21, 2027 to Sep 16, 2026
AstraZenecaPhase 1 NCT07220954 Registry history of NCT07220954 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 100 participants (planned 50)
AstraZenecaPhase 1 NCT07013643 Registry history of NCT07013643 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of May 31, 2027 to Jul 27, 2026
AstraZenecaPhase 3 NCT03847428 Registry history of NCT03847428 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 47 → 44 locations
AstraZenecaNot specified NCT06521229 Registry history of NCT06521229 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 44 → 40 locations
AstraZenecaPhase 1/2 NCT06749457 Registry history of NCT06749457 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaPhase 2 NCT06851858 Registry history of NCT06851858 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 28, 2028 to Oct 11, 2028
Also in this update: Study completion pushed from Jul 3, 2028 to Jul 18, 2029
AstraZenecaPhase 1/2 NCT07109219 Registry history of NCT07109219 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
AstraZenecaPhase 1 NCT07612813 Registry history of NCT07612813 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 23, 2026 to Nov 16, 2026; Final enrollment: 72 participants (planned 136)
AstraZenecaPhase 1 NCT06995820 Registry history of NCT06995820 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaPhase 1 NCT07622433 Registry history of NCT07622433 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaNot specified NCT07221981 Registry history of NCT07221981 on ClinicalTrials.gov (opens the registry)
Trial completed
AstraZenecaNot specified NCT06646419 Registry history of NCT06646419 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 65 → 39 locations; Final enrollment: 159 participants (planned 300)
AstraZenecaNot specified NCT06031805 Registry history of NCT06031805 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jul 14, 2026 to May 6, 2026; Final enrollment: 48 participants (planned 150)
AstraZenecaNot specified NCT07024680 Registry history of NCT07024680 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 21, 2026 to Dec 8, 2026
AstraZenecaPhase 1 NCT07290283 Registry history of NCT07290283 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 6, 2026 to Oct 23, 2026
Also in this update: Enrollment increased: 14 → 16 participants
AstraZenecaPhase 2 NCT07017179 Registry history of NCT07017179 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 57 → 63 participants
Also in this update: Trial sites expanded: 63 → 96 locations; and 6 more changes in the last 30 days
AstraZenecaPhase 2 NCT06824987 Registry history of NCT06824987 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 30, 2027 to Jun 30, 2027
AstraZenecaNot specified NCT06175637 Registry history of NCT06175637 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 132 → 151 locations
AstraZenecaPhase 3 NCT07611110 Registry history of NCT07611110 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 48 → 34 locations
AstraZenecaPhase 3 NCT07520162 Registry history of NCT07520162 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 311 → 314 locations
AstraZenecaPhase 3 NCT07431281 Registry history of NCT07431281 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 150 → 166 participants
AstraZenecaPhase 4 NCT06531798 Registry history of NCT06531798 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 269 → 272 locations
AstraZenecaPhase 3 NCT06467357 Registry history of NCT06467357 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 219 → 226 locations
AstraZenecaPhase 3 NCT06921785 Registry history of NCT06921785 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 24 → 32 participants
AstraZenecaPhase 1 NCT07402915 Registry history of NCT07402915 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 167 → 190 participants
Also in this update: Primary completion date changed from estimate of Aug 3, 2028 to Jun 16, 2026
AstraZenecaPhase 1 NCT05647122 Registry history of NCT05647122 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 247 → 231 locations
Also in this update: Study completion moved earlier from Feb 28, 2029 to Nov 12, 2027; Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026
AstraZenecaPhase 3 NCT05984277 Registry history of NCT05984277 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 68 → 82 locations
AstraZenecaPhase 3 NCT07215585 Registry history of NCT07215585 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 150 → 154 locations
AstraZenecaPhase 3 NCT06307665 Registry history of NCT06307665 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 276 → 284 locations
AstraZenecaPhase 3 NCT06878261 Registry history of NCT06878261 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 144 → 147 locations
AstraZenecaPhase 2 NCT07276581 Registry history of NCT07276581 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 468 → 471 locations
AstraZenecaPhase 3 NCT05624450 Registry history of NCT05624450 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 672 → 679 locations
AstraZenecaPhase 3 NCT07761117 Registry history of NCT07761117 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 177 → 183 locations
AstraZenecaPhase 3 NCT07221253 Registry history of NCT07221253 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 295 → 300 locations
AstraZenecaPhase 3 NCT06627647 Registry history of NCT06627647 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 228 → 235 locations
AstraZenecaPhase 3 NCT06549595 Registry history of NCT06549595 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 190 → 195 locations
AstraZenecaPhase 2 NCT07652658 Registry history of NCT07652658 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 15 locations
AstraZenecaNot specified NCT07633158 Registry history of NCT07633158 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 24 locations
AstraZenecaNot specified NCT07607769 Registry history of NCT07607769 on ClinicalTrials.gov (opens the registry)
Primary and study completion moved earlier from Dec 31, 2027 to Nov 30, 2027
AstraZenecaPhase 3 NCT06764186 Registry history of NCT06764186 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Sep 15, 2028 to Aug 10, 2028
Also in this update: Primary completion moved earlier from Feb 11, 2028 to Jan 6, 2028
AstraZenecaPhase 1/2 NCT06137118 Registry history of NCT06137118 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Aug 24, 2026 to Jun 26, 2026
AstraZenecaPhase 3 NCT04711252 Registry history of NCT04711252 on ClinicalTrials.gov (opens the registry)
Interventions modified
AstraZenecaPhase 3 NCT07776509 Registry history of NCT07776509 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jun 30, 2027 to Mar 31, 2027
Also in this update: Primary completion date changed from estimate of Jun 30, 2027 to Jul 10, 2026
AstraZenecaPhase 3 NCT06564844 Registry history of NCT06564844 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Sep 28, 2026 to Aug 14, 2026
AstraZenecaPhase 2 NCT07143604 Registry history of NCT07143604 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 1, 2026 to May 27, 2027
AstraZenecaPhase 2 NCT06040099 Registry history of NCT06040099 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jan 30, 2026 to Nov 30, 2026
AstraZenecaPhase 1 NCT02546661 Registry history of NCT02546661 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-16 | NCT07877818 A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant… | Phase 3 | Not Yet Recruiting |
| 2026-10-15 | NCT07876817 A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and… | Phase 4 | Not Yet Recruiting |
| 2026-10-01 | NCT07851025 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous… | Phase 3 | Recruiting |
| Phase 1 | 58 | |
| Phase 1/2 | 49 | |
| Phase 2 | 72 | |
| Phase 2/3 | 2 | |
| Phase 3 | 189 | |
| Phase 4 | 15 |
Lung Cancer (103) · Non-Small Cell Lung Cancer (NSCLC) (82) · Breast Cancer (53) · Asthma (30) · Prostate Cancer (27) · Lupus (SLE) (26) · Ovarian Cancer (24) · Leukemia (21) · Gastric Cancer (18) · Liver Cancer (18)